Author:
Economides Aris N.,Carpenter Laura Rocco,Rudge John S.,Wong Vivien,Koehler-Stec Ellen M.,Hartnett Christopher,Pyles Erica A.,Xu Xiaobing,Daly Thomas J.,Young Michael R.,Fandl James P.,Lee Frank,Carver Scott,McNay Jennifer,Bailey Kevin,Ramakanth Swayampakula,Hutabarat Renta,Huang Tammy T.,Radziejewski Czeslaw,Yancopoulos George D.,Stahl Neil
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference37 articles.
1. van Deventer, S.J. Anti-TNF antibody treatment of Crohn's disease. Ann. Rheum. Dis. 58 (Suppl. 1), I114–1120 (1999).
2. Richard-Miceli, C. & Dougados, M. Tumour necrosis factor-α blockers in rheumatoid arthritis: Review of the clinical experience. Biodrugs 15, 251–259 (2001).
3. Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36, 1681–1690 (1993).
4. Goldenberg, M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 21, 75–87 (1999).
5. Mohler, K.M. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548–1561 (1993).
Cited by
336 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献